Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
The LancetPublished 1 July 1998
Lars Sjöström, Aila Rissanen, Teis Andersen, Mark Boldrin, Alain Golay, H. P. F. Koppeschaar
Citations1,203
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period and the use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.
Abstract
Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period. The use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.
Keywords
Medicine
JAMAIncreasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991
2,387 Citations1994Robert J. Kuczmarski
Observed trends in overweight prevalence and body mass index of the US adult population suggest that the Healthy People 2000 objective of reducing the prevalence of overweight US adults to no more than 20% may not be met by the year 2000.
JAMAIncreasing Prevalence of Overweight Among US Adults
1,570 Citations1994Robert J. Kuczmarski
Observations suggest that the Healthy People 2000 objective of reducing the prevalence of overweight US adults to no more than 20% may not be met by the year 2000.
PubMedBeneficial health effects of modest weight loss.
920 Citations1992D J Goldstein
In conclusion, a large proportion of obese individuals with NIDDM, hypertension, and hyperlipidemia experienced positive health benefits with modest weight loss, and even a small amount of weight loss appears to benefit a substantial subset of obese patients.
PubMedDietary fat and obesity: evidence from epidemiology.
431 Citations1995Lauren Lissner, Berit L. Heitmann
A review of various epidemiological methods used to address the development of obesity as well as an updated summary of the existing evidence are provided.
The LancetINTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY
310 Citations1989B Guy-Grand, Gaetano Crepaldi +4 more
In a randomised, placebo-controlled, double-blind study, 822 obese patients of both sexes were given either dexfenfluramine, 15 mg twice daily (404), or placebo in addition to a calorie-restricted diet for 1 year.
Clinical Pharmacology & TherapeuticsRetrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers
280 Citations1994Jianguo Zhi, Angela T. Melia +5 more
The model‐fitting suggests the existence of a steep portion of the dose‐response curve up to approximately 400 mg/day, with a subsequent tendency to plateau at higher doses, which was instrumental in identifying appropriate doses to be used in therapeutic trials for weight loss in obese patients.
PubMedThe role of dietary fat in obesity.
234 Citations1997Alain Golay, E Bobbioni
Dietary fat induces overconsumption and weight gain through its low satiety properties and high caloric density and it is suggested that periodic exposure to a high-fat meal, particularly when hunger is high, may be sufficient to lead to overcons consumption of energy as fat in obese patients.
PubMedOrlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
209 Citations1995Marjolein Drent, Ingrid Larsson +7 more
Orlistat, in an apparently dose-dependent manner, leads to additional weight loss compared to diet alone and overall, is well tolerated.
Human Energy Requirements: A Manual for Planners and Nutritionists
185 Citations1990W. P. T. James, Eugene Schofield-Georgeson
An overview of energy requirements and allowances and the impact of urbanization and population structure and different assumptions on estimated allowances is provided.
Obesity ResearchRelationships Between Changes in Body Composition and Changes in Cardiovascular Risk Factors: The SOS Intervention Study
181 Citations1997C. David Siöström, Lauren Lissner +1 more
The use of waist as a single risk factor indicator seems less effective for epidemiological studies than the simple anthropometric measures presented here, which are able to separate the effects of visceral AT mass, subcutaneous At mass, and sub cutaneous AT distribution on metabolic parameters under both cross-sectional and longitudinal conditions.
American Journal of Clinical NutritionInitial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)
179 Citations1992JB Hauptman, FS Jeunet +1 more
Initial studies in humans have shown that Ro 18-0647 can reliably increase fecal fat excretion and further research must be conducted to determine whether clinical endpoints of weight loss or cholesterol lowering can be produced by using this new pharmacologic principle.
Hormone and Metabolic ResearchTime Trends in Obesity: An Epidemiological Perspective
173 Citations1997Jacob C. Seidell
A closer look at data from The Netherlands suggest that average weight increase in the order of about 1 kilo can be responsible for quite dramatic increases in the prevalence of obesity and that only small changes in the daily caloric balance may be sufficient to increase the number of obese subjects in populations.
Journal of Epidemiology & Community HealthTrends in body mass index and prevalence of obesity in Swedish men 1980-89.
151 Citations1993A Kuskowska-Wolk, R. Bergström
During the 1980s the mean BMI and the prevalence of overweight and obesity among adult Swedish men increased.
PubMedLipase inhibition: a novel concept in the treatment of obesity.
151 Citations1993Marjolein Drent, E. A. van der Veen
Orlistat (Ro 18-0647) is an inhibitor of gastric, carboxylester and pancreatic lipase and specifically reduces the absorption of dietary fat due to the inhibition of triglyceride hydrolysis and can be used for the treatment of obesity.
The Journal of Clinical PharmacologyThe Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Absorption of Vitamins A and E in Healthy Volunteers
118 Citations1996Angela T. Melia, Susan G. Koss‐Twardy +1 more
Orlistat significantly reduced the absorption of vitamin E but not that of vitamin A, at the dose levels studied, which will aid in the implementation of a vitamin supplementation strategy, should vitamin deficiency occur in patients undergoing orlistat therapy.
PubMedAdipose tissue cellularity in relation to prognosis for weight reduction.
101 Citations1977M Krotkiewski, L Sjöström +4 more
The long-term prognosis for weight reduction is worse for hypercellular forms of obesity than for the hypertrophic form, however, this does not mean that patients with hyper Cellular Forms of obesity should not be treated at all since their serious spontaneous weight development might be lessened by repeated treatments.
European Journal of Clinical PharmacologyThe effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia
93 Citations1994Serena Tonstad, D Pometta +9 more
Orlistat is a new therapeutic drug for the treatment of hyperlipidaemia that may be particularly useful among overweight patients and its potential place in therapy will await long-term studies.
Journal of Epidemiology & Community HealthTrends in body mass index and prevalence of obesity in Swedish women 1980-89.
74 Citations1993A Kuskowska-Wolk, R. Bergström
During the 1980s the mean BMI and the prevalence of overweight and obesity in adult Swedish women increased and an influence of the sociocultural environment on the body weight in women was stronger than that in men.
The Journal of Clinical PharmacologyThe Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Pharmacokinetics of β‐Carotene in Healthy Volunteers
66 Citations1996Jianguo Zhi, Angela T. Melia +3 more
It was concluded that two thirds of a supplemental dose ofβ‐carotene will be absorbed during orlistat treatment; this may be sufficient to achieve physiologic levels of β‐ carotene with an appropriate dose of β-carotenes, should supplementation be needed in obese patients who have developed β‐Carotene deficiency during therapy with or listat.
New England Journal of MedicineDiet Pills Redux
47 Citations1997Gregory Curfman
Between 1967 and 1972, there was a serious outbreak of primary pulmonary hypertension in Western Europe, which was traced to the use of an appetite-suppressant drug, aminorex (Menocil), which had been introduced in Europe shortly before.